Evaluation of Quality of Life and Survival With MS-20 in Patient With Advanced Hepatocellular Carcinoma (FDA IND 74572)
NCT ID: NCT00707681
Last Updated: 2010-02-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
60 participants
INTERVENTIONAL
2008-03-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
I
MS-20
MS-20
4 ml/vial
2
Placebo
Placebo
4ml/vial
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MS-20
4 ml/vial
Placebo
4ml/vial
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Subject aged ≧ 20;
2. Histologically documented, unresectable advanced HCC. For patients with difficulty in obtaining histological diagnosis, a "clinical diagnosis" of HCC is acceptable if all the following criteria are met:
* Chronic hepatitis B or C with evidence of liver cirrhosis;
* Presence of hepatic tumor(s) with image findings (sonography, CT scan) compatible with HCC and no evidence of gastrointestinal tumors;
* Elevated serum α-fetoprotein level ≧ 400 ng/ml;
3. Cancer of the Liver Italian Program (CLIP) score of 3-4;
4. Liver transaminase ≦ 5 times upper normal limits (UNL);
5. Patient fulfilling any of the follow conditions:
* Refuse to receive aggressive cancer therapy after explained to the subjects the benefits and risks;
* Progressive malignant disease after previous radiotherapy, percutaneous ethanol injection, radiofrequency ablation, transarterial embolization, transarterial chemoembolization, systemic chemotherapy, immunotherapy, or any experimental therapy, or unable to tolerate such therapy;
* No treatment of high priority is available;
6. ECOG performance status of 0 - 2;
7. Patients are willing and able to comply with study procedures and sign informed consent.
Exclusion Criteria
1. Patient with history of HCC rupture;
2. Medical condition requiring anticoagulant or anti-platelet drugs;
3. Patients with brain metastases;
4. Patient unable to receive oral medication;
5. Patients with significant renal function impairment (creatinine\>1.5mg/dl), severe cardiac disease, e.g. angina pectoris, myocardial infarction, cardiac arrhythmia, congestive heart failure (New York Heart Association Functional Classification III and IV) or physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that might render the subject at high risk from treatment;
6. Female subjects of childbearing potential who:
* are lactating; or
* have positive pregnancy test (urine) at V2;
7. Active infection or on antiretroviral therapy for HIV disease;
8. Patient with known hypersensitivity to any component of the study medication (soy bean or soy product).
20 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Microbio Co Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
MicroBio Co., Ltd.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cheng-Yuan Peng, MD
Role: PRINCIPAL_INVESTIGATOR
China Medical University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
China Medical University Hospital
Taichung, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Cheng-Yuan Peng, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MCRA06001A
Identifier Type: -
Identifier Source: org_study_id